Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3451 AL 3465

How plausible is an Alzheimer's disease vaccine?

Cacabelos R.

Expert Opin Drug Discov. 2020 Jan;15(1):1-6. doi: 10.1080/17460441.2019.1667329. Epub 2019 Sep 17.

Phosphodiesterase inhibitors say NO to Alzheimer's disease

Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, Tewari D, Argüelles S, Mehrzadi S, Hosseinzadeh A, D'onofrio G, Orhan IE, Sureda A, Xu S, Momtaz S, Farzaei MH.

Food Chem Toxicol. 2019 Dec;134:110822. doi: 10.1016/j.fct.2019.110822. Epub 2019 Sep 16.

Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents

Pourshojaei Y, Eskandari K, Asadipour A.

Mini Rev Med Chem. 2019;19(19):1577-1598. doi: 10.2174/1389557519666190719143112.

Comparative pharmacokinetic study of the components in Alpinia oxyphylla Miq.-Schisandra chinensis (Turcz.) Baill. herb pair and its single herb between normal and Alzheimer's disease rats by UPLC-MS/MS

Qi Y, Cheng X, Jing H, Yan T, Xiao F, Wu B, Bi K, Jia Y.

J Pharm Biomed Anal. 2020 Jan 5;177:112874. doi: 10.1016/j.jpba.2019.112874. Epub 2019 Sep 12.

Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease

Venugopal A, Iyer M, Balasubramanian V, Vellingiri B.

Acta Neuropsychiatr. 2020 Apr;32(2):65-71. doi: 10.1017/neu.2019.39. Epub 2019 Dec 26.

Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders

Benfante R, Di Lascio S, Cardani S, Fornasari D.

Aging Clin Exp Res. 2021 Apr;33(4):823-834. doi: 10.1007/s40520-019-01359-4. Epub 2019 Oct 3.

Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach

Dorababu A.

Bioorg Chem. 2019 Dec;93:103299. doi: 10.1016/j.bioorg.2019.103299. Epub 2019 Sep 19.

How does a researcher choose the best rodent model for their Alzheimer's disease drug discovery study?

Van Dam D, De Deyn PP.

Expert Opin Drug Discov. 2020 Mar;15(3):269-271. doi: 10.1080/17460441.2020.1676719. Epub 2019 Oct 8.

Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

Kabir MT, Uddin MS, Begum MM, Thangapandiyan S, Rahman MS, Aleya L, Mathew B, Ahmed M, Barreto GE, Ashraf GM.

Curr Pharm Des. 2019;25(33):3519-3535. doi: 10.2174/1381612825666191008103141.

Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease

Morsy A, Trippier PC.

J Alzheimers Dis. 2019;72(s1):S145-S176. doi: 10.3233/JAD-190744.

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective

Derry PJ, Hegde ML, Jackson GR, Kayed R, Tour JM, Tsai AL, Kent TA.

Prog Neurobiol. 2020 Jan;184:101716. doi: 10.1016/j.pneurobio.2019.101716. Epub 2019 Oct 8.

NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy

Kabir MT, Sufian MA, Uddin MS, Begum MM, Akhter S, Islam A, Mathew B, Islam MS, Amran MS, Md Ashraf G.

Curr Pharm Des. 2019;25(33):3506-3518. doi: 10.2174/1381612825666191011102444.

Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD

Dyer AH, Murphy C, Lawlor B, Kennelly SP; NILVAD Study Group.

J Am Med Dir Assoc. 2020 Feb;21(2):194-200. doi: 10.1016/j.jamda.2019.08.006. Epub 2019 Oct 8.

Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies

Chen JY, Zhu Q, Zhang S, OuYang D, Lu JH.

Pharmacol Res. 2019 Dec;150:104476. doi: 10.1016/j.phrs.2019.104476. Epub 2019 Oct 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias